Results 141 to 150 of about 168,609 (265)

Lymphocyte‐C‐Reactive Protein Ratio as Promising New Marker for Predicting Surgical Site Infection in Children With Ulcerative Colitis

open access: yesAnnals of Gastroenterological Surgery, Volume 10, Issue 5, Page 1586-1593, September 2026.
This study identifies the preoperative lymphocyte‐to–C‐reactive protein ratio (LCR) as a potent and independent biomarker for predicting surgical site infection (SSI) in pediatric patients undergoing major surgery for ulcerative colitis. ROC analysis established an optimal cutoff of 5000 (AUC: 0.80), which demonstrated robust predictive performance ...
Yuhki Koike   +9 more
wiley   +1 more source

[Treatment of internal rectal fistulae].

open access: yesVestnik khirurgii imeni I. I. Grekova, 1980
Under consideration is the classification of internal anal fistulas and indications to the corresponding methods of operation. The authors describe the techniques of their operations. The observations were performed of 81 patients with internal anal fistulas.
N M, Blinnichev, R M, Buttaev
openaire   +1 more source

Single‐Incision Laparoscopy‐First Strategy in Crohn's Disease: Risk Factors for Conversion and Surgical Outcomes

open access: yesAnnals of Gastroenterological Surgery, Volume 10, Issue 5, Page 1602-1611, September 2026.
In this retrospective study of 289 patients with Crohn's disease undergoing a single‐incision laparoscopy‐first (SILS‐first) strategy, conversion to open surgery was required in only 11.8% of cases. Fistula formation, colon resection, and smoking history were identified as independent risk factors for conversion, while postoperative complications and ...
Yuki Horio   +9 more
wiley   +1 more source

Identification of major congenital malformations based on healthcare databases in France: A proof‐of‐concept study using the epi‐meres nationwide mother–child register

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 9, Page 3037-3048, September 2026.
Abstract Aim Besides registries, healthcare databases can provide useful information for assessing the frequency of major congenital malformations (MCMs) and investigating their risk factors, particularly medication exposures. This study aimed to assess the validity of MCMs identification based on French national, comprehensive healthcare databases ...
Tom Duchemin   +7 more
wiley   +1 more source

Cardiovascular Immune‐Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta‐Summary of Case Reports

open access: yesCancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Reports of immune checkpoint inhibitor (ICI) therapy‐associated immune‐related adverse events (irAEs) exhibit considerable heterogeneity, particularly when comparing data from clinical trials and real‐world observational studies. Methods We conducted a systematic review of real‐world observational studies (case reports and series ...
Shea‐Lee Godin   +4 more
wiley   +1 more source

Mesenchymal Stem Cells Alleviate Crohn's Disease by Regulating CBS‐Mediated Ferroptosis

open access: yesImmunity, Inflammation and Disease, Volume 14, Issue 9, September 2026.
MSCs alleviate CD by regulating CBS‐mediated ferroptosis. Bioinformatics analysis identified CBS as a hub gene shared by CD and ferroptosis. In TNBS‐induced colitis mice, MSCs treatment alleviated intestinal inflammation by upregulating CBS expression, increasing GSH and GPX4 levels, and inhibiting ferroptosis.
Zhixi Huang   +13 more
wiley   +1 more source

The vesicosigmoidal fistula: diagnosis and surgical tretment

open access: yes, 1987
The authors report their experience in the diagnosis and treatment of 10 cases of vesicosigmoidal fistula. In accordance with the literature the most frequent presenting symptoms were of urinary origin.
Comunale L.   +8 more
core  

Indicators of Suboptimal Treatment Among Patients With Crohn's Disease Treated With Ustekinumab or Risankizumab and Treatment Journey Among Ustekinumab Discontinuers in the United States

open access: yesJCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Background and Aims Patients with Crohn's disease (CD) may experience suboptimal response to advanced therapies (ATs), including interleukin (IL)‐12/23 inhibitor ustekinumab and IL‐23 inhibitor risankizumab. In an evolving treatment landscape, this study evaluated indicators of suboptimal treatment with these agents. Methods This retrospective
Freddy Caldera   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy